Baring Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Baring Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$486K	Hold	5,222	–	–	0.03%	165
2017 Q2	$475K	Hold	5,222	–	–	0.03%	163
2017 Q1	$458K	Sell	5,222 -32,199	-86%	-$2.86M	0.03%	168
2016 Q4	$3.1M	Hold	37,421	–	–	0.21%	87
2016 Q3	$3.46M	Hold	37,421	–	–	0.25%	82
2016 Q2	$2.91M	Sell	37,421 -170	-0.5%	-$14.5K	0.24%	82
2016 Q1	$3.1M	Hold	37,591	–	–	0.26%	75
2015 Q4	$3.94M	Hold	37,591	–	–	0.33%	73
2015 Q3	$3.96M	Sell	37,591 -292	-0.8%	-$39K	0.36%	73
2015 Q2	$5.18M	Hold	37,883	–	–	0.42%	68
2015 Q1	$4.72M	Sell	37,883 -1,816	-5%	-$192K	0.37%	69
2014 Q4	$3.59M	Sell	39,699 -22,769	-36%	-$1.89M	0.23%	87
2014 Q3	$4.51M	Buy	+62,468	New	+$4.11M	0.27%	87

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baring Asset Management's BMRN Position: Q3 2017 in Review

Baring Asset Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2017 at 5,222 shares worth $486K. The position accounts for 0.03% of the portfolio, ranked #165.

Baring Asset Management first reported a position in BMRN in Q3 2014 and has held it in 13 quarters since. The position peaked at $5.18M in Q2 2015. 411 funds tracked by Wall St. Rank hold BMRN as of Q3 2017.

Baring Asset Management held 5,222 shares of BioMarin Pharmaceuticals worth $486K as of Q3 2017.
Baring Asset Management left its BioMarin Pharmaceuticals share count unchanged in Q3 2017.
BioMarin Pharmaceuticals made up 0.03% of Baring Asset Management's portfolio in Q3 2017, its #165 holding.
Baring Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2014 and has held it in 13 quarters since.
Baring Asset Management's BioMarin Pharmaceuticals position peaked at $5.18M in Q2 2015.
411 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2017.

Based on Baring Asset Management's 13F filing for Q3 2017, filed 26 Oct 2017.